#Japan #Tokyo #Prolacta #Clinigen #PreemieFort®

Clinigen Breaks New Ground in Infant Nutrition with Approval of PreemieFort® Enteral Solution

In an unprecedented achievement, Clinigen has received approval for Prolacta Bioscience's PreemieFort® Enteral Solution as a legitimate pharmaceutical product in Japan. This human milk-based fortifier is designed to aid in the nutritional management of neonates and infants suffering from weight gain issues, particularly very low birth weight (VLBW) infants. The approval sets a remarkable precedent in regulatory practices and signifies a leap forward in infant care.

The endorsement of PreemieFort® comes as a result of extensive research, particularly the JASMINE Phase III clinical trial. This trial was a randomized, open-label study focusing on VLBW infants, demonstrating the efficacy and safety of the product. It's important to note that, while Prolacta's solution is categorized as an infant formula in the U.S. and Europe, this new designation in Japan marks the first instance of a human milk-based nutritional fortifier being classified as a prescription drug. This is a significant stride in addressing the nutritional requirements of vulnerable infants in a region known for its high standards in neonatal care.

Clinigen K.K., in collaboration with Prolacta Bioscience®, navigated this complex regulatory landscape to achieve a successful outcome. According to Dr. Varun Sethi, Clinigen's CEO, this collaborative effort involved defining a pathway where none existed, ultimately ensuring that quality, safety, and efficacy standards were met. Dr. Sethi stated, "This not only unlocks market potential for our partner but also directly addresses the needs of vulnerable infants, ensuring that access is determined by the quality of care rather than geographic limitations."

As the exclusive licensee and Marketing Authorization Holder for this product in Japan, Clinigen plays a critical role in bridging the gap between the innovative potential of Prolacta's offerings and the stringent requirements of the Japanese regulatory framework. The approval of PreemieFort® underscores the increasing importance of regulated human milk derivatives, especially in the context of neonatal healthcare strategies.

Scott Elster, CEO of Prolacta, expressed pride in this accomplishment, highlighting the collaborative effort that went into achieving this groundbreaking regulatory approval. He noted that this milestone paves the way for improved access to specialized nutrition for at-risk infants not only in Japan but potentially across other regions.

This recent regulatory victory emphasizes Clinigen's commitment to navigating intricate environments that challenge market access for specialized healthcare products. The implications of this approval are far-reaching; it not only elevates the standards of care available to eligible infants but also reinforces the necessity of robust regulatory frameworks to ensure ongoing improvements in patient outcomes.

Prolacta's PreemieFort® Enteral Solution is explicitly indicated for VLBW infants, as well as other neonates and infants exhibiting failure to gain weight due to conditions such as gastrointestinal disorders or congenital heart diseases. The approval of this innovative product represents a critical step in ensuring the nutritional needs of vulnerable populations are met, affirming the role of human milk as an essential component in medical nutrition for infants.

In conclusion, the successful approval of PreemieFort® in Japan showcases Clinigen's regulatory expertise and commitment to advancing infant healthcare. By leveraging their deep understanding of market dynamics and regulatory complexities, Clinigen and Prolacta are set to make a notable difference in the lives of infants and their families.